Form Bio Announces FORMsightAI, a Breakthrough AI Solution Set for Predicting and Optimizing Cell & Gene Therapy Manufacturability

New Offering Enables Therapy Developers and CDMOs to Simulate Bioreactor Runs and Optimize Therapeutic Constructs for Yield and Safety

DALLAS, May 11, 2023--(BUSINESS WIRE)--Form Bio, the provider of advanced computational life sciences technology, announced today the launch of FORMsight^AI – a new, AI-based solution set for predicting and optimizing manufacturing outputs of cell and gene therapy constructs. Form Bio FORMsight^AI is generally available to cell and gene therapy companies as well as CDMOs.

Form Bio FORMsight^AI is a full service solution that incorporates advanced, customizable AI models, Form Bio’s underlying platform and the company’s experienced team of computational life sciences professionals with expertise spanning biology, bioinformatics and data science.

FORMsight^AI addresses common issues faced by cell and gene therapy developers of construct truncations and manufacturing contaminations, which are key contributors to unsustainably low manufacturing yields, delayed times-to-market and therapeutic safety issues. Using patent-pending large language models, in conjunction with the Form Bio platform, cell and gene therapy developers can now, for the first time, predictively analyze and avoid key manufacturing risk factors before scaling up manufacturing.

"Nearly every cell and gene therapy company we talk to faces the extremely challenging issues of capital burn, time-to-market and cost per dose. But few of them, until now, have been able to fully recognize the staggering costs of under addressing manufacturing issues at the earliest stages of therapy development," said Andrew Busey, co-founder and co-CEO for Form Bio. "Now, with our FORMsight^AI solution, cell and gene therapy companies can not only measure this multi-billion dollar problem, but also minimize it," he added.

The FORMsight^AI offering is comprised of two core components:

• FORMsight^AI SIMULATE for predicting key metrics of bioreactor run outputs including capsid fill statistics, truncation propensities, regional truncation contribution and more.

• FORMsight^AI OPTIMIZE for generating an optimal payload construct design with the ideal predicted capsid fill metrics, full reads and minimized truncations.

By utilizing FORMsight^AI solutions, cell and gene therapy companies, as well as CDMOs, can recognize these powerful benefits:

• Reduce manufacturing costs by simulating the therapeutic output of a construct before spending millions of dollars on bioreactor runs.

• Reduce time-to-market by minimizing manufacturing trial-and-error relating to identifiable construct contamination propensities.

• Improve safety by predicting and optimizing capsid fill rates before expending time and resources on test production.

• Extend IP protection by filing fresh patents on newly optimized constructs generated by FORMsight^AI.

In addition, a publicly traded gene therapy company has used the solution and was able to predictively reduce truncations of one of its candidates by 70% and increase full reads by 18%.

"As a customer, we are thrilled with the uniquely valuable AI-driven insights Form Bio has contributed to our research and development efforts," said Jenny Marlowe, Chief Scientific Officer for Solid Biosciences. "By working closely with Form Bio’s world class team and cutting-edge technology, we can clearly see that applying innovative AI solutions to pre-clinical cell and gene therapy development offers exciting potential for CGT companies’ economics, market timing and ability to impact human health," she added.

The complete solution is customizable and is underpinned by the company’s comprehensive computational life sciences platform which includes nearly everything biopharma professionals and academic researchers need for data management, workflow execution, data visualization and research collaboration. FORMsight^AI SIMULATE and FORMsight^AI OPTIMIZE can be purchased separately or in combination with each other. For more details and pricing visit https://www.formbio.com/get-demo.

Additional resources:
FORMsight^AI on FormBio.com
FORMsight^AI Solution Overview (PDF)
FORMsight^AI SIMULATE Data Sheet (PDF)
FORMsight^AI OPTIMIZE Data Sheet (PDF)
Gene Therapy Case Study (PDF)

About Form Bio

Form Bio is a life sciences focused software company dedicated to empowering scientific discovery and enabling a new era of insights and breakthroughs. With an award winning, easy-to-use research and discovery platform as well as powerful AI solutions for specific biopharma challenges, Form Bio accelerates therapeutic research, design and development. In addition to providing innovative technology, Form works collaboratively with customers to advance their most ambitious scientific objectives, offering unmatched, cross-disciplinary expertise spanning software engineering, biology, bioinformatics and data science. For more information on Form Bio, visit formbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005360/en/

Contacts

Maggie Whitney
mwhitney@cglife.com
203-957-1502